Privi Speciality Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Privi Speciality Chemicals reported its Q2 and H1 FY26 (ended September 30, 2025) results with a sharp divergence between standalone and consolidated performance. On a standalone basis, revenue from operations fell to Rs. 578.25 crore in Q2 (vs Rs. 656.50 crore in Q2 FY25) and H1 revenue dropped about 21% YoY to Rs. 959.42 crore, with standalone PAT nearly halving to Rs. 78.50 crore in H1 (vs Rs. 167.98 crore). On a consolidated basis, however, H1 revenue grew about 24% YoY to Rs. 1,237.53 crore and consolidated PAT more than doubled to Rs. 155.84 crore, indicating strong contribution from subsidiaries (Privi Biotechnologies, Prigiv Specialities, and US arm). The statutory auditor BSR & Co. LLP issued an unmodified (clean) limited review report on both sets of results. The company operates in a single segment - Aroma Chemicals.
Mixed signals for shareholders: standalone business is clearly under pressure with steep revenue and profit declines, but the group-level picture is far stronger, driven by subsidiaries. Investors should watch whether the standalone weakness is a temporary pricing/volume issue or a structural concern, while the strong consolidated growth from subsidiaries is a positive sign for the overall franchise.